经中国证券监督管理委员会 2019 年 9 月 27 日证监许可[2019]1794 号文核准，公 司向社会公开发行人民币普通股 50,000,000 股，每股面值人民币 1.00 元，每股发行价 格为人民币 6.99 元，募集资金总额为人民币 349,500,000.00 元，由主承销商中信证券 扣除保荐承销费 29,680,000.00 元后，将剩余募集资金 319,820,000.00 元汇入公司在下 列银行开立的募集资金专用账户。扣除公司后期为发行股份所支付的其他发行费用 12,053,400.00 元，扣除公司应转出的先期以自有资金垫付其他发行费用 3,416,018.23 元， 加上应归还募集资金账户的发行费用进项税 2,551,270.23 元，实际募集资金净额为 306,901,852.00 元，其中计入股本 50,000,000.00 元，资本溢价 256,901,852.00 元计入资 本公积，新增股本占新增注册资本的 100%。上述资金于 2019 年 10 月 24 日全部到位， 业经立信会计师事务所（特殊普通合伙）验证，并出具信会师报字[2019]第 ZA15706 号 《验资报告》 ...

关于赛诺医疗科学技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 2、 附表 目 录 委托单位：赛诺医疗科学技术股份有限公司 审计单位：立信会计师事务所（特殊普通合伙） 联系电话：021-63391166 1、 专项审计报告 赛诺医疗科学技术股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 二〇二四年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.mof.gov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:///acc.mof.gov.cn）"进行查看 "一 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 关于赛诺医疗科学技术股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZA11723 号 赛诺医疗科学技术股份有限公司全体股东: 我们审计了赛诺医疗科学技术股份有限公司(以下简称"赛诺医 疗")2024年度的财务报表,包括 2024年12月 31日的合并 ...

赛诺医疗科学技术股份有限公司 审计报告及财务报表 二〇二四年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.cnof.gov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查 。 䎋䈪५⯇、ᆖᢰᵟ㛑ԭᴹ䲀ޜਨ ᇑ䇑ᣕ৺䍒࣑ᣕ㺘 ˄2024 ᒤ 01 ᴸ 01 ᰕ㠣 2024 ᒤ 12 ᴸ 31 ᰕ→˅ | | ⴞᖅ | 亥⅑ | | --- | --- | --- | | аǃ | ᇑ䇑ᣕ੺ | 1-5 | | Ҽǃ | 䍒࣑ᣕ㺘 | | | | ਸᒦ䍴ӗ䍏٪㺘઼⇽ޜਨ䍴ӗ䍏٪㺘 | 1-4 | | | ਸᒦ࡙⏖㺘઼⇽ޜਨ࡙⏖㺘 | 5-6 | | | ਸᒦ⧠䠁⍱䟿㺘઼⇽ޜਨ⧠䠁⍱䟿㺘 | 7-8 | | | ਸᒦᡰᴹ㘵ᵳ⳺ਈࣘ㺘઼⇽ޜਨᡰᴹ㘵ᵳ⳺ਈࣘ㺘 | 9-12 | | | 䍒࣑ᣕ㺘䱴⌘ | 1-100 | йǃ ޣ䭞ᇑ䇑һ亩 ᇑ䇑ᣕ ؑՊᐸᣕᆇ[2025]ㅜ ZA11721 ਧ 䎋䈪५⯇、ᆖᢰᵟ㛑ԭᴹ䲀ޜਨޘփ㛑ь˖ аǃ ᇑ䇑㿱 ᡁԜᇑ䇑Ҷ䎋䈪५⯇、ᆖᢰᵟ㛑ԭᴹ䲀ޜਨ˄ԕлㆰ〠䎋䈪५⯇˅ ...

Financial Performance - The company's revenue for Q3 2024 reached ¥104,794,180.69, representing a year-on-year increase of 25.76%[2] - The net loss attributable to shareholders was ¥14,406,461.69, with a year-to-date loss of ¥10,915,893.04[2] - The company reported a year-to-date increase of 30.20% in revenue, primarily driven by a significant rise in coronary product sales[6] - The net profit attributable to shareholders for the year-to-date period increased by 73.85%, influenced by revenue growth and lower growth rates in operating costs and sales expenses[6] - Total operating revenue for the first three quarters of 2024 reached CNY 318,486,443.24, an increase of 30.2% compared to CNY 244,617,074.10 in the same period of 2023[17] - The net loss for the first three quarters of 2024 was CNY 14,931,400.83, compared to a net loss of CNY 44,634,324.37 in the same period of 2023, indicating an improvement[18] Research and Development - Research and development expenses totaled ¥59,721,899.55 for the quarter, an increase of 58.46% compared to the same period last year[2] - R&D expenses accounted for 56.99% of total revenue, up 11.76 percentage points year-on-year[2] - The company is focusing on key milestone clinical trial expenses as part of its ongoing R&D projects[7] - Research and development expenses surged to CNY 106,407,498.18, a significant increase of 32.3% from CNY 80,498,702.34 in the previous year[17] Assets and Liabilities - Total assets increased by 6.83% from the end of the previous year, reaching ¥1,266,868,249.18[3] - Total assets reached ¥1,266,868,249.18, compared to ¥1,185,821,379.98, marking a growth of approximately 6.8%[14] - The total liabilities increased to CNY 381,227,223.14 from CNY 324,171,588.85, marking a growth of 17.6%[16] - Non-current liabilities rose to CNY 224,486,551.62, up from CNY 172,899,093.28, reflecting a 29.8% increase[16] - The company's total equity increased to CNY 885,641,026.04 from CNY 861,649,791.13, showing a growth of 2.8%[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥49,720,487.28, reflecting a 37.18% increase[2] - Cash inflow from operating activities for the first three quarters of 2024 was $379,785,264.54, an increase of 18.4% compared to $320,671,351.90 in the same period of 2023[21] - Net cash flow from operating activities increased to $49,720,487.28, up 37.2% from $36,245,821.18 year-over-year[21] - Cash inflow from financing activities rose to $121,906,687.94, compared to $63,000,000.00 in the previous year, marking a significant increase of 93.5%[22] - The ending cash and cash equivalents balance increased to $224,939,661.92, compared to $189,369,325.44 at the end of the same period last year, reflecting a growth of 18.8%[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,402[9] - The largest shareholder, Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd., holds 71,859,417 shares, accounting for 17.38% of total shares[9] - The company has not reported any significant changes in the shareholding structure or related party transactions among the top shareholders[10] Operational Insights - There are no significant reminders or additional important information regarding the company's operational situation during the reporting period[12] - The company plans to continue its market expansion and product development strategies to enhance future performance[20] - The cash flow statement for the first three quarters of 2024 indicates ongoing financial challenges, with net cash flow from operating activities remaining a focus area[19] Accounting Practices - The company did not apply new accounting standards for the current year, maintaining consistency in financial reporting[23]

Financial Performance - The company's operating revenue for Q1 2024 was ¥91,062,636.90, representing a year-on-year increase of 24.46%[5] - The net profit attributable to shareholders was -¥1,672,840.41, with a significant increase in net loss compared to the previous year[5] - Total revenue for Q1 2024 reached ¥91,062,636.90, a 24.4% increase from ¥73,168,207.49 in Q1 2023[18] - Net profit for Q1 2024 was a loss of ¥3,684,677.11, an improvement from a loss of ¥18,642,741.10 in Q1 2023[19] - Total comprehensive income for Q1 2024 was a loss of ¥5,003,621.26, compared to a loss of ¥19,139,644.82 in Q1 2023[19] Research and Development - Research and development expenses totaled ¥40,560,514.19, accounting for 44.54% of operating revenue, an increase of 2.99 percentage points year-on-year[6] - The company added eLum to its consolidated scope, contributing to increased R&D costs across various categories[9] - Research and development expenses rose to ¥36,009,056.49 in Q1 2024, up 35.4% from ¥26,583,394.30 in Q1 2023[18] - Research and development expenses for Q1 2024 were CNY 7,076,116.53, down from CNY 8,715,645.88 in Q1 2023, reflecting a decrease of approximately 18.8%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,275,418,626.59, reflecting a 7.56% increase from the end of the previous year[6] - The company's total current assets rose to CNY 307,807,885.11, compared to CNY 286,299,842.73 at the end of 2023, marking an increase of about 7.4%[24] - The total liabilities of the company were RMB 395,630,423.74, which is an increase from RMB 324,171,588.85, representing a growth of around 22.1%[15] - The company's long-term liabilities increased to RMB 235,587,162.35 from RMB 172,899,093.28, representing a growth of approximately 36.3%[15] - The total liabilities increased to CNY 301,940,030.53 as of March 31, 2024, compared to CNY 240,066,782.01 at the end of 2023, showing an increase of about 25.7%[25] Cash Flow - Operating cash flow for Q1 2024 showed a net outflow of ¥16,218,315.41, compared to a net outflow of ¥19,993,202.99 in Q1 2023[21] - The company generated ¥87,527,487.94 in cash from financing activities in Q1 2024, compared to ¥17,000,000.00 in Q1 2023[22] - The net cash flow from operating activities was -CNY 9,478,350.67, an improvement from -CNY 12,337,600.64 in the same period last year[30] - The net cash flow from financing activities was CNY 72,818,883.96, up from CNY 19,298,666.67 in Q1 2023, indicating a strong increase in financing[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,173, with the largest shareholder holding 17.53% of the shares[10] - The company's equity attributable to shareholders was RMB 817,378,486.78, slightly down from RMB 819,957,004.39, showing a decrease of about 0.3%[16] - The total owner's equity reached CNY 1,103,981,155.96 as of March 31, 2024, slightly up from CNY 1,099,238,457.97 at the end of 2023, reflecting a growth of about 0.4%[25] Earnings Per Share - The basic and diluted earnings per share were both -¥0.004, indicating a 90% increase in loss per share compared to the previous year[9] - Basic and diluted earnings per share for Q1 2024 were both -¥0.004, an improvement from -¥0.04 in Q1 2023[19]

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥213,692,262.55, representing a 32.49% increase compared to ¥161,285,944.35 in the same period last year[20]. - The net profit attributable to shareholders was ¥3,490,568.65, a significant recovery from a loss of ¥29,611,147.98 in the previous year[20]. - The total assets increased by 9.93% to ¥1,303,564,738.46 from ¥1,185,821,379.98 at the end of the previous year[20]. - The net assets attributable to shareholders rose by 5.79% to ¥867,403,664.40 from ¥819,957,004.39 at the end of the previous year[20]. - The basic and diluted earnings per share were both ¥0.01, reflecting a growth of 114.29% year-on-year[25]. - The weighted average return on equity was 0.42%, up by 3.96 percentage points from the previous year[25]. - The net cash flow from operating activities was ¥13,002,580.28, down 16.72% from ¥15,612,531.32 in the same period last year[20]. - The net profit attributable to shareholders reached CNY 7.662 million, marking a significant increase of 125.88% compared to the previous year[94]. - The company's operating revenue growth was primarily driven by a 70.77% increase in coronary intervention business revenue, attributed to the implementation of the national centralized procurement policy for coronary stents[97]. Research and Development - Research and development expenses accounted for 43.16% of operating revenue, a decrease of 6.69 percentage points year-on-year[25]. - The company achieved a total R&D investment of CNY 92.23 million, accounting for 43.16% of its revenue[47]. - The company has developed a total of 22 products across 6 categories in the coronary and neurovascular fields, enhancing its product diversification and risk resistance[67]. - The company has established a comprehensive R&D platform for new product development, focusing on innovative drug delivery systems[42]. - The company has received multiple patent authorizations for its retractable, self-locking mitral valve replacement technology, aimed at providing a minimally invasive treatment for severe mitral regurgitation[51]. - The company has a structured emergency response plan for potential environmental incidents, ensuring efficient and orderly management[133]. - The company is advancing research on supercritical carbon dioxide (sc-CO2) technology, with a budget of 6.46 million RMB aimed at evaluating its feasibility in interventional products by 2024[62]. Market and Product Development - The coronary intervention business revenue grew by 70.77%, driven by increased sales of stent and balloon products[23]. - The company is focusing on expanding its product offerings and enhancing its research capabilities in the biomedical engineering sector[31]. - The company has successfully launched multiple leading coronary and neurointerventional products, with cumulative usage reaching nearly 2 million across over 3,000 hospitals in China and benefiting hundreds of thousands of patients in Southeast Asia, Europe, and South America[35]. - The company is expanding its product line with the introduction of the TORR negative pressure suction pump, aimed at enhancing surgical suction capabilities in hospitals[40]. - The company is actively developing new products, including the OLLIEE™ and HONKYTONK™ balloon catheters, aimed at improving myocardial perfusion in patients with coronary artery disease[38]. - The company has made significant progress in developing multiple new products in the neurointerventional field, with all projects proceeding as planned[49]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - Despite significant growth in revenue and net profit, the company still faces risks of continuous losses in 2024 due to competitive pressures and ongoing centralized procurement initiatives[89]. - The company faces risks related to new product development failures or registration delays due to high technical barriers and regulatory challenges in the medical device industry[79]. - There is a risk of talent loss if the company cannot provide competitive compensation and a conducive work environment[80]. - The company is exposed to risks from centralized procurement policies, which may affect sales volume and pricing strategies[83]. Corporate Governance and Compliance - The report is unaudited, and the board of directors has confirmed the accuracy and completeness of the financial report[5]. - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for this reporting period[7]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[166]. - The company has maintained a good credit status with no records of violations in the past three years[168]. - The company has not reported any significant litigation or arbitration matters during the reporting period[167]. Environmental and Social Responsibility - The company invested RMB 28.17 million in environmental protection during the reporting period[128]. - The company has established a comprehensive environmental protection mechanism and all pollution control facilities are operating effectively[130]. - The company has no administrative penalties related to environmental issues during the reporting period[135]. - The company has a structured emergency response plan for potential environmental incidents, ensuring efficient and orderly management[133].

赛诺医疗科学技术股份有限公司2025 年第一季度报告 证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真实、 准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期 增减变动幅度(%) | | --- | --- | --- | --- | | 营业收入 | 100,849,103.23 | 91,062,636.90 | 10.75 | | 归属于上市公司股东的净利润 | 2,969,330.70 | -1,672,840.41 | 不适用 | | ...

赛诺医疗科学技术股份有限公司 2024 年度独立董事述职报告（马元驹） 根据中国证监会《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《赛诺医疗科学技术股份有限公司 章程》《赛诺医疗科学技术股份有限公司独立董事工作规则》的有关规定，作为赛诺医疗 科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）的独立董事，本人马元驹在 2024年度工作中能够认真、勤勉、忠实、独立地履行独立董事的各项职责，审慎行使公司 及股东赋予的权利，积极发挥独立董事的监督作用，认真审议各项议案，发挥专业特长， 为公司经营发展提出合理化建议，对公司董事会审议的相关重大事项发表独立客观的意见， 为董事会的科学决策提供支持，促进公司规范、可持续发展，切实维护了公司和股东尤其 是中小股东的合法权益。现将2024年度履行职责情况报告如下： 一、独立董事基本情况 公司董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数的三分之一，符合相 关法律法规及公司制度的规定。 （一）个人工作履历、专业背景以及兼职情况 马元驹，男，汉族，1957年3月生，上海财经大学经济学硕士、中国人 ...

赛诺医疗科学技术股份有限公司 根据中国证监会《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《赛诺医疗科学技术股份有限公司 章程》《赛诺医疗科学技术股份有限公司独立董事工作规则》的有关规定，作为赛诺医疗 科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）的独立董事，本人高岩在 2024年度工作中能够认真、勤勉、忠实、独立地履行独立董事的各项职责，审慎行使公司 及股东赋予的权利，积极发挥独立董事的监督作用，认真审议各项议案，发挥专业特长， 为公司经营发展提出合理化建议，对公司董事会审议的相关重大事项发表独立客观的意见， 为董事会的科学决策提供支持，促进公司规范、可持续发展，切实维护了公司和股东尤其 是中小股东的合法权益。现将2024年度履行职责情况报告如下： 高岩，男，1966年1月出生，中国国籍，无境外永久居留权。北京大学学士（计算数学专 业）、美国密执安州立大学硕士、美国西北大学金融博士，注册金融师。1988至1990年，任北 京物资学院教师；2001年至2003年任美国纽约城市大学访问教授；2003年至2004年任美国加 州州立大学洛杉 ...

赛诺医疗科学技术股份有限公司 （一）个人工作履历、专业背景以及兼职情况 李蕊, 女，1978 年出生，中国国籍，无境外永久居留权。中国人民大学经济法学学士、 中国政法大学民商法学硕士、中国人民大学经济法学博士，中国政法大学经济法学博士后、 美国明尼苏达大学访问学者。2015 年至 2017 年，任职于北京农学院法学系。2017 年起任中 国政法大学民商经济法学院教授，博士生导师，中国政法大学地方财政金融与农村法治研究 中心主任。兼任中国法学会经济法学研究会常务理事、中国法学会财税法学研究会常务理事、 中国农业农村法研究会常务理事、中国法学会银行法学研究会理事等。2020 年 12 月至今担 任赛诺医疗独立董事。 （二）独立董事担任董事会专门委员会的情况 2020年12月至今，本人在公司董事会薪酬与考核委员会担任主任委员，在董事会提名 委员会担任委员。 2024 年度独立董事述职报告（李蕊） 根据中国证监会《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立 董事管理办法》《上海证券交易所科创板股票上市规则》《赛诺医疗科学技术股份有限公司 章程》《赛诺医疗科学技术股份有限公司独立董事工作规则》的有关规 ...